Form 4: Adicet Bio Director Lloyd Klickstein Acquires 70,200 Stock Options
SEC Form 4 Filing
Director Lloyd Klickstein acquired 70,200 stock options in Adicet Bio, Inc. on August 19, 2024, according to a Form 4 filing.
Summary
- On August 19, 2024, Lloyd Klickstein, a director of Adicet Bio, Inc., acquired 70,200 stock options.
- The exercise price of these options is $1.55.
- The options vest in 36 equal monthly installments starting August 19, 2024, but vesting ceases if Klickstein leaves the Board of Directors.
- The options expire on August 18, 2034.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants to a director, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially impacting shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of transaction: Lloyd Klickstein acquired 70,200 stock options. |
| 08/19/2024 | Vesting start date: Stock options vest in 36 equal monthly installments. |
| 08/18/2034 | Expiration date: Stock options expire. |
| 08/20/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.